7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mitochondria-Targeted Peptide SS31 Attenuates Renal Tubulointerstitial Injury via Inhibiting Mitochondrial Fission in Diabetic Mice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Renal tubular injury is an early characteristic of diabetic nephropathy (DN) that is related to mitochondrial dysfunction. In this study, we explore the effects and mechanisms of mitochondria-targeted peptide SS31 on renal tubulointerstitial injury in DN.

          Method

          40 C57BL/6 mice were randomly divided into control group, STZ group, STZ+SS31 group, and STZ+normal saline group. SS31 was intraperitoneally injected to the mice every other day for 24 weeks. Renal lesions and the expression of Drp1, Mfn1, Bcl-2, Bax, Caspase1, IL-1 β, and FN were detected. In in vitro studies, HK-2 cells were incubated with different concentrations of D-glucose (5, 30 mM) or combined with SS31 and Drp1 inhibitor Midivi1. Mitochondrial ROS, membrane potential, and morphology have been detected to evaluate the mitochondrial function.

          Results

          Compared with diabetic mice, the levels of serum creatinine and microalbuminuria were significantly decreased in the SS31 group. Renal tubulointerstitial fibrosis, oxidative stress, and apoptosis were observed in diabetic mice, while the pathological changes were reduced in the SS31-treatment group. SS31 could decrease the expression of Drp1, Bax, Caspase1, IL-1 β, and FN in the renal tissue of diabetic mice, while increasing the expression of Mfn1. Additionally, mitochondria exhibit focal enlargement and crista swelling in renal tubular cells of diabetic mice, while SS31 treatment could partially block these changes. An in vitro study showed that pretreatment with SS31 or Drp1 inhibitor Mdivi1 could restore the level of mitochondrial ROS, the membrane potential levels, and the expressions of Drp1, Bax, Caspase1, IL-1 β, and FN in HK-2 cells under high-glucose conditions.

          Conclusion

          SS31 protected renal tubulointerstitial injury in diabetic mice through a decrease in mitochondrial fragmentation via suppressing the expression of Drp1 and increasing the expression of Mfn1.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Mitochondrial energetics in the kidney

          Mitochondria provide the kidney with energy to remove waste from the blood and regulate fluid and electrolyte balance. This Review discusses how mitochondrial homeostasis is maintained, the changes in mitochondrial energetics that occur in acute kidney injury and diabetic nephropathy, and how targeting mitochondrial energetics might aid the treatment of renal disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A glimpse of various pathogenetic mechanisms of diabetic nephropathy.

            Diabetic nephropathy is a well-known complication of diabetes and is a leading cause of chronic renal failure in the Western world. It is characterized by the accumulation of extracellular matrix in the glomerular and tubulointerstitial compartments and by the thickening and hyalinization of intrarenal vasculature. The various cellular events and signaling pathways activated during diabetic nephropathy may be similar in different cell types. Such cellular events include excessive channeling of glucose intermediaries into various metabolic pathways with generation of advanced glycation products, activation of protein kinase C, increased expression of transforming growth factor β and GTP-binding proteins, and generation of reactive oxygen species. In addition to these metabolic and biochemical derangements, changes in the intraglomerular hemodynamics, modulated in part by local activation of the renin-angiotensin system, compound the hyperglycemia-induced injury. Events involving various intersecting pathways occur in most cell types of the kidney.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.

              Chronic kidney disease (CKD) is a common comorbidity in patients with type 2 diabetes mellitus (T2DM) and both conditions are increasing in prevalence. CKD is estimated to affect ∼50% patients with T2DM globally, and its presence and severity markedly influences disease prognosis. CKD is more common in certain patient populations, including the elderly, those with youth-onset diabetes mellitus, those who are obese, certain ethnic groups, and disadvantaged populations. These same settings have also seen the greatest increase in the prevalence of T2DM, as exemplified by the increasing prevalence of T2DM in low-to- middle income countries. Patients from low-to-middle income countries are often the least able to deal with the burden of T2DM and CKD and the health-care facilities of these countries least able to deal with the demand for equitable access to renal replacement therapies. The increasing prevalence of younger individuals with T2DM, in whom an accelerated course of complications can be observed, further adds to the global burden of CKD. Paradoxically, improvements in cardiovascular survival in patients with T2DM have contributed to patients surviving longer, allowing sufficient time to develop renal impairment. This Review explores how the changing epidemiology of T2DM has influenced the prevalence and incidence of associated CKD across different populations and clinical settings.
                Bookmark

                Author and article information

                Contributors
                Journal
                Oxid Med Cell Longev
                Oxid Med Cell Longev
                OMCL
                Oxidative Medicine and Cellular Longevity
                Hindawi
                1942-0900
                1942-0994
                2019
                2 June 2019
                : 2019
                : 2346580
                Affiliations
                1Department of Nephrology, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China
                2Department of Clinical Laboratory, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China
                3Institute of Kidney Disease, Central South University, Changsha, Hunan Province, China
                4International Medicine Department, Ningbo First Hospital, Zhejiang University, Ningbo, China
                Author notes

                Academic Editor: Victor M. Victor

                Author information
                http://orcid.org/0000-0002-6552-0176
                http://orcid.org/0000-0002-8165-6698
                http://orcid.org/0000-0002-4762-0333
                http://orcid.org/0000-0003-1698-0616
                http://orcid.org/0000-0002-3194-3488
                http://orcid.org/0000-0002-2049-3485
                Article
                10.1155/2019/2346580
                6589270
                31281569
                e5ad3114-aa66-4c16-bce9-fdecd640269d
                Copyright © 2019 Shi-kun Yang et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 21 January 2019
                : 10 April 2019
                : 23 April 2019
                Funding
                Funded by: Natural Science Foundation of Zhejiang Province
                Award ID: LQ16H050001
                Funded by: Central South University
                Award ID: JY201521
                Funded by: Natural Science Foundation of Hunan Province
                Award ID: 2018JJ3785
                Funded by: National Natural Science Foundation of China
                Award ID: 81600566
                Award ID: 81870498
                Award ID: 8197033544
                Award ID: 81500558
                Categories
                Research Article

                Molecular medicine
                Molecular medicine

                Comments

                Comment on this article